Urologic Cancer Drug Costs in Low- and Middle-Income Countries
Open Access
- 16 October 2024
- journal article
- review article
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 5 (5) , 312-319
Abstract
All 189 World Bank member countries are classified by their capita gross national income into one of four income groups. In this review, we aim to explore the economic burden and management of urologic oncology conditions in low- and middle-income countries (LMICs), emphasizing disparities and challenges in treatment access. The current World Bank classification system highlights economic stratification, showing significant health outcome disparities, particularly in urologic oncology conditions including kidney, bladder, and prostate cancer. First, this review focuses on the management of advanced prostate cancer in Asian LMICs, revealing higher mortality-to-incidence ratios and a greater prevalence of metastatic disease compared to high-income countries (HICs). The prohibitive costs of novel hormonal therapies (NHTs) like abiraterone and enzalutamide limit their use and exacerbate outcome disparities. Second, we review Wilms tumor treatment with chemotherapy in African countries, noting significant price variations for adapted and non-adapted regimens across different economic settings. The cost of chemotherapy agents, particularly dactinomycin, acts as a primary driver of treatment expenses, underscoring the economic challenges in providing high-quality care. Lastly, bladder cancer treatment costs in Brazil and Middle Eastern countries are examined, highlighting how detrimental the economic burden of intravesical therapies, like mitomycin C and Bacillus Calmette–Guérin (BCG), is on treatment accessibility. Overall, this literature review emphasizes the financial strain on healthcare systems and patients, particularly in regions facing economic instability and drug shortages, and underscores the need for international cooperation and effective resource allocation to address the economic barriers to urologic care in LMICs, aiming to improve health outcomes and ensure equitable access to advanced treatments.Keywords
This publication has 16 references indexed in Scilit:
- Cost of bladder cancer in Lebanon before and after the economic collapse: a probabilistic modeling studyInternational Journal for Equity in Health, 2023
- Understanding the needs of low‐income countries: how urologists can helpBJU International, 2021
- Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high‐ and middle‐income Asian countriesCancer Science, 2021
- Challenges facing the urologist in low- and middle-income countriesWorld Journal of Urology, 2020
- Cost and cost-effectiveness of childhood cancer treatment in low-income and middle-income countries: a systematic reviewBMJ Global Health, 2019
- Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 studyEuropean Journal of Cancer, 2019
- Improved outcome at end of treatment in the collaborative Wilms tumour Africa projectPediatric Blood & Cancer, 2018
- Treating childhood cancer in Rwanda: the nephroblastoma examplePan African Medical Journal, 2015
- The Collaborative Wilms Tumour Africa Project; Baseline evaluation of Wilms tumour treatment and outcome in eight institutes in sub-Saharan AfricaEuropean Journal of Cancer, 2015
- SIOP PODC: Clinical guidelines for the management of children with Wilms tumour in a low income settingPediatric Blood & Cancer, 2012